Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 5.36 is 57% below its 5-year average of 12.54, near the low end of its 5-year range (5.28–20.27).
As of the fiscal period ended Tuesday, June 30, 2026. 25.22% below its 12-month average of 7.16.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.36.
CURRENT RATIO
5.36
CURRENT RATIO AVG TTM
7.16
CURRENT RATIO AVG 3Y
11.30
CURRENT RATIO AVG 5Y
12.54
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-25.22%
CURRENT VS 3Y AVG
-52.61%
CURRENT VS 5Y AVG
-57.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.54
median of 768 covered companies
CURRENT VS SECTOR MEDIAN
+51.10%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$218.59M
Current Ratio
5.36
TTM Avg
7.16
3Y Avg
11.30
5Y Avg
12.54
Market Cap
$218.36M
Current Ratio
344.31
TTM Avg
177.51
3Y Avg
95.19
5Y Avg
76.57
Market Cap
$221.57M
Current Ratio
21.96
TTM Avg
18.45
3Y Avg
17.11
5Y Avg
21.15
Market Cap
$214.35M
Current Ratio
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$209.27M
Current Ratio
20.05
TTM Avg
17.55
3Y Avg
12.54
5Y Avg
12.54
Market Cap
$208.90M
Current Ratio
7.48
TTM Avg
9.04
3Y Avg
6.33
5Y Avg
4.86
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $218.59M | 5.36 | 7.16 | 11.30 | 12.54 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.36M | 344.31 | 177.51 | 95.19 | 76.57 |
| Alector, Inc. (ALEC)vs › | $216.72M | 5.26 | 3.62 | 4.54 | 4.95 |
| Keros Therapeutics, Inc. (KROS)vs › | $221.57M | 21.96 | 18.45 | 17.11 | 21.15 |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 6.50 | 4.21 | 3.36 | 3.03 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | 4.07 | 3.65 | 6.88 | 10.38 |
| Compugen Ltd. (CGEN)vs › | $211.33M | 5.72 | 5.91 | 5.85 | 7.15 |
| Sionna Therapeutics, Inc. (SION)vs › | $209.27M | 20.05 | 17.55 | 12.54 | 12.54 |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.90M | 7.48 | 9.04 | 6.33 | 4.86 |
| Profound Medical Corp. (PROF)vs › | $229.65M | 6.45 | 11.52 | 11.11 | 13.89 |
Current Ratio
5.36
Quick Ratio
5.36
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 5.36 |
| 2026-03-31 | 7.23 |
| 2025-12-31 | 5.28 |
| 2025-09-30 | 10.30 |
| 2025-06-30 | 7.65 |
| 2025-03-31 | 7.49 |
| 2024-12-31 | 7.06 |
| 2024-09-30 | 13.43 |
| 2024-06-30 | 16.19 |
| 2024-03-31 | 16.51 |
| 2023-12-31 | 16.07 |
| 2023-09-30 | 16.74 |
| 2023-06-30 | 17.63 |
| 2023-03-31 | 20.27 |
| 2022-12-31 | 17.59 |
| 2022-09-30 | 12.88 |
| 2022-06-30 | 13.26 |
| 2022-03-31 | 15.24 |
| 2021-12-31 | 13.40 |
| 2021-09-30 | 10.65 |
| 2021-06-30 | 13.11 |
| 2021-03-31 | 10.73 |
| 2020-12-31 | 12.53 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
